BioGaia Past Earnings Performance

Past criteria checks 2/6

BioGaia ha aumentado sus ingresos a un ritmo medio anual de 16.6%, mientras que la industria Biotechs ha visto aumentar sus ingresos growing a 17.4% anualmente. Los ingresos han crecido growing a un ritmo medio anual de 11%. BioGaia La rentabilidad de los fondos propios de la empresa es de 22% y sus márgenes netos son de 34.4%.

Key information

17.7%

Earnings growth rate

13.3%

EPS growth rate

Biotechs Industry Growth17.0%
Revenue growth rate12.0%
Return on equity18.0%
Net Margin28.2%
Next Earnings Update23 Jul 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown
Beta

How BioGaia makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

OTCPK:BIOG.Y Revenue, expenses and earnings (SEK Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 231,297365403107
30 Sep 231,273437399110
30 Jun 231,213415387111
31 Mar 231,186413377101
31 Dec 221,104374361107
30 Sep 221,036273341106
30 Jun 22952246302103
31 Mar 22867222262103
31 Dec 21785196231105
30 Sep 21767196206105
30 Jun 21725164198105
31 Mar 21766188197104
31 Dec 20747180198105
30 Sep 2076719420399
30 Jun 20802211210105
31 Mar 20780193213106
31 Dec 19768187209105
30 Sep 19770192200111
30 Jun 19778205195110
31 Mar 19756207192107
31 Dec 18742215181100
30 Sep 1870220617394
30 Jun 1867519716686
31 Mar 1863118115378
31 Dec 1761518114976
30 Sep 1758417914370
30 Jun 1756217213969
31 Mar 1754216313267
31 Dec 1653516012964
30 Sep 1650013811857
30 Jun 1648012911453
31 Mar 1647813011152
31 Dec 1548313811253
30 Sep 1550013011560
30 Jun 1547411911459
31 Mar 154329711558
31 Dec 1448214710754
30 Sep 1445114610246
30 Jun 144331459843
31 Mar 144261429342
31 Dec 13316629441
30 Sep 13298609241
30 Jun 13299619339

Beneficios de calidad: BIOG.Y tiene ganancias de alta calidad.

Creciente margen de beneficios: BIOG.YLos actuales márgenes de beneficio netos de (28.2%) son inferiores a los del año pasado (33.9%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Tendencia de beneficios: BIOG.YLos beneficios de la empresa han crecido un 16.6% al año en los últimos 5 años.

Acelerando crecimiento: BIOG.Y's ha tenido un crecimiento negativo de los beneficios en el último año, por lo que no puede compararse con su media de 5 años.

Beneficios vs. Industria: BIOG.Y tuvo un crecimiento negativo de los beneficios (-2.3%) durante el año pasado, lo que dificulta la comparación con la media del sector Biotechs (-8.1%).


Return on Equity

Alto ROE: El Retorno sobre el capital de BIOG.Y (18%) se considera bajo.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.